MASH – Talk Bio

Behind-the-Scenes Details of 89bio’s $2.4B Deal with Roche

3 weeks ago talkbio0Tagged biotech acquisition, Conditional, Deal Structure, Liver diseases, MASH, milestone payments, pegozafermin, Roche (company)

Roche; 89bio; pegozafermin; MASH; liver disease; contingent value rights; biotech acquisition; pharmaceuticals; deal structure; milestone payments

Roche Acquires 89bio with $2.4 Billion Buyout to Enter FGF21 MASH Therapeutics Space

1 month ago talkbio0Tagged Acquisition, cardiometabolic diseases, Conditional, fibroblast growth factor 21, Liver diseases, MASH, metabolic dysfunction-associated steatohepatitis, pegozafermin, Roche (company)

Roche; 89bio; acquisition; FGF21; pegozafermin; MASH; metabolic dysfunction-associated steatohepatitis; liver disease; biotech; contingent value rights; cardiometabolic diseases

FDA Considers Noninvasive Endpoint for MASH Trials, Boosts Biotech Shares

2 months ago talkbio0Tagged Altimmune, Biological Markers, Clinical Trials, Inventiva, Liver diseases, Madrigal Pharmaceuticals, MASH, Noninvasive Endpoint, stocks, United States Food and Drug Administration, Viking Therapeutics

FDA; noninvasive endpoint; liver disease; MASH; clinical trials; biomarker; biotech stocks; Madrigal Pharmaceuticals; Viking Therapeutics; Inventiva; Altimmune

FDA Grants Wegovy 3rd Indication: First GLP-1 Approved for MASH with Moderate-to-Advanced Liver Scarring

2 months ago talkbio0Tagged Accelerated, Approved, Fibrosis, Liver, MASH, noncirrhotic, Nordisk, Product containing glucagon-like peptide 1 receptor agonist (product), semaglutide, United States Food and Drug Administration, Wegovy

Wegovy; FDA approval; MASH; semaglutide; GLP-1 receptor agonist; liver fibrosis; Novo Nordisk; ESSENCE trial; noncirrhotic; accelerated approval

Madrigal Pharmaceuticals Inks up to $2B Deal with CSPC for Preclinical Oral GLP-1, Plans Combination with Rezdiffra for MASH

3 months ago talkbio0Tagged Combined Modality Therapy, global license agreement, GZMH gene, Madrigal Pharmaceuticals, MASH, milestone payments, oral small molecule, Pharmaceutical Group, preclinical drug, Product containing glucagon-like peptide 1 receptor agonist (product), Rezdiffra

Madrigal Pharmaceuticals; CSPC Pharmaceutical Group; GLP-1 receptor agonist; SYH2086; Rezdiffra; MASH; oral small molecule; preclinical drug; global license agreement; combination therapy; milestone payments

Altimmune’s Incretin Misses Fibrosis Improvement Endpoints in MASH Trial

4 months ago talkbio0Tagged Altimmune, Clinical Trials, Fibrosis, Glucagon-Like Peptide 1, Incretins, MASH, pemvidutide

Altimmune; incretin; pemvidutide; fibrosis; MASH; GLP-1; clinical trial

GSK Acquires Phase III-Ready Liver Drug Efimosfermin for Up to $2B to Enter MASH Arena

5 months ago talkbio0Tagged Analog, Boston Pharmaceuticals, drug acquisition, efimosfermin alfa, fibroblast growth factor 21, Liver diseases, MASH, Phase III, SLC17A5 gene, SmithKline Beecham

GSK; Boston Pharmaceuticals; efimosfermin alfa; Phase III; liver disease; MASH; SLD; drug acquisition; FGF21 analog

Inventiva Slashes Workforce and Pipeline to Focus on MASH Drug Lanifibranor

9 months ago talkbio0Tagged Inventiva, lanifibranor, MASH, Phase 3 trial, pipeline, restructuring

Inventiva, layoffs, pipeline reduction, lanifibranor, MASH, Phase 3 trial, biotech restructuring

Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships

9 months ago talkbio0Tagged AdvanCell, alpha therapies, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, MASH, OliX, Radiopharmaceuticals, strategic collaborations

Eli Lilly, AdvanCell, OliX Pharmaceuticals, targeted alpha therapies, radiopharmaceuticals, MASH, cardiometabolic diseases, strategic collaborations

Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies

9 months ago talkbio0Tagged AdvanCell, alpha therapies, Cancer Therapeutic Procedure, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, Interferes with, MASH, OliX, Radiopharmaceuticals, RNA

Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment